Akorn, Inc. (AKRX)
-NasdaqGS 13.32 
0.17(1.26%) 2:10PM EDT - Nasdaq Real Time Price
| Prev Close: | 13.49 |
|---|
| Open: | 13.45 |
|---|
| Bid: | 13.36 x 200 |
|---|
| Ask: | 13.37 x 400 |
|---|
| 1y Target Est: | 16.44 |
|---|
| Beta: | 0.65 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 13.31 - 13.57 |
|---|
| 52wk Range: | 11.73 - 16.87 |
|---|
| Volume: | 213,263 |
|---|
| Avg Vol (3m): | 573,756 |
|---|
| Market Cap: | 1.28B |
|---|
| P/E (ttm): | 34.37 |
|---|
| EPS (ttm): | 0.39 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Akorn Becomes Oversold (AKRX)at Forbes(Wed 12:45PM EDT)
- Can This Experimental Drug Be Brought Back From the Dead?at Motley Fool(Wed, Jun 12)
- AKRX Crosses Below Key Moving Average Levelat Forbes(Wed, Jun 5)
- AKORN INC FinancialsEDGAR Online Financials(Fri, May 17)
- AKORN INC Files SEC form 8-K/A, Changes in Registrant's Certifying AccountantEDGAR Online(Tue, May 14)
- AKORN INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- Akorn sell-off on Q1 results overdone, says Leerinkat theflyonthewall.com(Wed, May 8)
- Akorn Hits Estimates in Solid Quarterat Motley Fool(Tue, May 7)
- Vitamin Shoppe, Fossil, Akorn are big moversAP(Tue, May 7)
- Akorn's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, May 7)
- Why Akorn Shares Were Crushedat Motley Fool(Tue, May 7)
- AKRX Crosses Below Key Moving Average Levelat TheStreet(Tue, May 7)
- Akorn Earnings: Here’s Why Investors Don’t Like These Resultsat Wall St. Cheat Sheet(Tue, May 7)
- Q1 2013 Akorn, Inc. Earnings Release - Before Market OpenCCBN(Tue, May 7)
- Akorn Reports First Quarter 2013 Financial ResultsBusiness Wire(Tue, May 7)
Key Statistics
| Forward P/E (1 yr): | 16.92 |
|---|
| P/S (ttm): | 4.66 |
|---|
| Ex-Dividend Date: | 24-May-91 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 0.55 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.13 |
|---|
| Mean Recommendation*: | 2.1 |
|---|
| PEG Ratio (5 yr expected): | 1.09 |
|---|
Business Summary
Akorn, Inc. engages in the manufacture and marketing of diagnostic and therapeutic ophthalmic pharmaceuticals products, hospital drugs, and injectable pharmaceuticals in the United States and internationally.
View More